- Home
- FSFG vs IPHA Comparison
FSFG vs IPHA Comparison
Compare FSFG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- IPHA
- Stock Information
- Founded
- FSFG 2008
- IPHA 1999
- Country
- FSFG United States
- IPHA France
- Employees
- FSFG N/A
- IPHA N/A
- Industry
- FSFG Savings Institutions
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FSFG Finance
- IPHA Health Care
- Exchange
- FSFG Nasdaq
- IPHA Nasdaq
- Market Cap
- FSFG 165.5M
- IPHA 160.1M
- IPO Year
- FSFG 2008
- IPHA 2019
- Fundamental
- Price
- FSFG $25.75
- IPHA $1.82
- Analyst Decision
- FSFG Strong Buy
- IPHA Strong Buy
- Analyst Count
- FSFG 3
- IPHA 1
- Target Price
- FSFG $31.50
- IPHA $11.00
- AVG Volume (30 Days)
- FSFG 54.7K
- IPHA 11.8K
- Earning Date
- FSFG 07-24-2025
- IPHA 03-27-2025
- Dividend Yield
- FSFG 2.46%
- IPHA N/A
- EPS Growth
- FSFG 159.10
- IPHA N/A
- EPS
- FSFG 2.81
- IPHA N/A
- Revenue
- FSFG $75,839,000.00
- IPHA $20,831,349.00
- Revenue This Year
- FSFG $0.06
- IPHA $209.83
- Revenue Next Year
- FSFG $8.60
- IPHA $83.15
- P/E Ratio
- FSFG $9.27
- IPHA N/A
- Revenue Growth
- FSFG N/A
- IPHA N/A
- 52 Week Low
- FSFG $17.75
- IPHA $1.29
- 52 Week High
- FSFG $30.94
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- FSFG 55.34
- IPHA 39.24
- Support Level
- FSFG $23.49
- IPHA $1.71
- Resistance Level
- FSFG $25.04
- IPHA $1.92
- Average True Range (ATR)
- FSFG 0.82
- IPHA 0.09
- MACD
- FSFG 0.17
- IPHA -0.00
- Stochastic Oscillator
- FSFG 79.30
- IPHA 37.93
About FSFG First Savings Financial Group Inc.
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.